| Literature DB >> 27611572 |
Bao Yi1, Liang Chen1, Renna Sa1, Ruqing Zhong1, Huan Xing1, Hongfu Zhang1.
Abstract
Atmospheric ammonia is a common problem in poultry industry. High concentrations of aerial ammonia cause great harm to broilers' health and production. For the consideration of human health, the limit exposure concentration of ammonia in houses is set at 25 ppm. Previous reports have shown that 25 ppm is still detrimental to livestock, especially the gastrointestinal tract and respiratory tract, but the negative relationship between ammonia exposure and the tissue of breast muscle of broilers is still unknown. In the present study, 25 ppm ammonia in poultry houses was found to lower slaughter performance and breast yield. Then, high-throughput RNA sequencing was utilized to identify differentially expressed genes in breast muscle of broiler chickens exposed to high (25 ppm) or low (3 ppm) levels of atmospheric ammonia. The transcriptome analysis showed that 163 genes (fold change ≥ 2 or ≤ 0.5; P-value < 0.05) were differentially expressed between Ammonia25 (treatment group) and Ammonia3 (control group), including 96 down-regulated and 67 up-regulated genes. qRT-PCR analysis validated the transcriptomic results of RNA sequencing. Gene Ontology (GO) functional annotation analysis revealed potential genes, processes and pathways with putative involvement in growth and development inhibition of breast muscle in broilers caused by aerial ammonia exposure. This study facilitates understanding of the genetic architecture of the chicken breast muscle transcriptome, and has identified candidate genes for breast muscle response to atmospheric ammonia exposure.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27611572 PMCID: PMC5017607 DOI: 10.1371/journal.pone.0162631
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The effects of atmospheric ammonia on growth performance and slaughter performance of 42-day AA broilers.
| 3 ± 3 ppm | 25 ± 3 ppm | |
|---|---|---|
| Group | Ammonia3 | Ammonia25 |
| ADFI | 158.42 ± 5.78 | 152.46 ± 7.69 |
| ADG | 99.41 ± 10.08 | 89.36 ± 12.32 |
| FCR | 1.64 ± 0.18 | 1.71 ± 0.23 |
| Slaughter rate (%) | 91.96 ± 0.35a | 89.38 ± 1.73b |
| half net carcass rate (%) | 85.74 ± 0.82 | 84.28 ± 1.46 |
| Whole net carcass rate (%) | 73.00 ± 0.86 | 72.34 ± 1.57 |
| Beast muscle ratio (%) | 23.61 ± 1.06a | 16.11 ± 2.47b |
ADFI, average daily feed intake; ADG, average daily gain; FCR, feed conversion ratio. Values a, b within a row indicate significant difference between groups at P < 0.05. Numbers are mean ± S.D.
Summary statistics for sequence quality and alignment information of breast muscle samples in two groups.
| Ammonia3_1 | Ammonia3_2 | Ammonia25_1 | Ammonia25_2 | |
|---|---|---|---|---|
| Ammonia3 | Ammonia3 | Ammonia25 | Ammonia25 | |
| 73,988,890 | 70,579,138 | 87,417,108 | 87,567,900 | |
| 9,248,611,250 | 8,822,392,250 | 10,927,138,500 | 10,945,987,500 | |
| 70,089,536 | 66,879,214 | 82,649,276 | 82,713,992 | |
| 8,757,428,504 | 8,356,297,248 | 10,326,600,930 | 10,334,744,020 | |
| 94.68% | 94.71% | 94.50% | 94.41% | |
| 94.75% | 94.79% | 94.64% | 94.58% | |
| 51.50% | 51.50% | 51.50% | 51.50% | |
| 49,313,882 | 47,427,718 | 59,205,224 | 58,723,920 | |
| 45,818,693 | 44,268,019 | 54,687,437 | 54,278,215 | |
| 3,495,189 | 3,159,699 | 4,517,787 | 4,445,705 | |
| 70.36% | 70.92% | 71.63% | 71.00% |
Fig 1The percentage of reads mapped to exonic, intronic and intergenic regions.
Fig 2Distribution of expression level (in FPKM) of transcripts.
Fig 3Volcano plot displaying differentially expressed genes between two groups.
Red dots (Up) represent significantly up-regulated genes (P < 0.05, fold change ≥ 2); green dots (Down) represent significantly down-regulated genes (P < 0.05, fold change ≤ 0.5); black dots (No) represent insignificantly differentially expressed genes.
Top ten up- and down-regulated genes in treatment group compared to control group.
| Gene ID | Gene symbol | Fold change | |
|---|---|---|---|
| NM_001277411.1 | -26.29 | 1.32E-07 | |
| NM_001167752.2 | -23.34 | 3.82E-02 | |
| XM_416332.4 | -18.90 | 6.41E-07 | |
| XM_004937841.1 | -16.88 | 3.11E-05 | |
| NM_001113709.1 | -11.67 | 5.48E-03 | |
| XM_416965.4 | -8.76 | 2.58E-20 | |
| XM_004940680.1 | -8.52 | 1.06E-16 | |
| XM_004946064.1 | -7.56 | 5.92E-05 | |
| XM_001234113.3 | -6.45 | 5.52E-15 | |
| NM_205446.1 | -5.62 | 3.49E-03 | |
| XM_418427.4 | 3.16 | 4.04E-02 | |
| XM_004934600.1 | 3.30 | 2.50E-03 | |
| NM_205028.1 | 3.47 | 1.08E-04 | |
| NM_001030966.1 | 3.86 | 9.10E-03 | |
| XM_417174.4 | 4.13 | 6.98E-17 | |
| XR_211672.1 | 4.46 | 1.59E-02 | |
| NM_001031288.1 | 4.82 | 9.32E-03 | |
| NM_001007477.3 | 4.88 | 9.83E-05 | |
| XM_004943064.1 | 5.52 | 1.47E-04 | |
| NM_001012846.1 | 5.61 | 1.25E-02 |
CA3, carbonic anhydrase III, muscle specific; MB, myoglobin; MYBPC1, myosin binding protein C, slow type, transcript variant X2; MYBPC1, myosin binding protein C, slow type, transcript variant X1; MYH1C, myosin, heavy chain 1C, skeletal muscle; METTL21C, methyltransferase like 21C; FHL1, four and a half LIM domains 1, transcript variant X4; MYH1G, myosin, heavy chain 1G, skeletal muscle (similar to human myosin, heavy chain 1, skeletal muscle, adult); FHL1, four and a half LIM domains 1, transcript variant X1; TPM2, tropomyosin 2 (beta); KHDRBS3, KH domain containing, RNA binding, signal transduction associated 3; AGPAT3, 1-acylglycerol-3-phosphate O-acyltransferase 3; CNTFR, ciliary neurotrophic factor receptor; INSIG1; insulin induced gene 1; DCUN1D5, DCN1, defective in cullin neddylation 1, domain containing 5 (S. cerevisiae), transcript variant X2; LOC101748992, uncharacterized LOC101748992; DHCR24, 24-dehydrocholesterol reductase; LOC396531, parvalbumin; 42436, membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein ligase; ACSBG2, acyl-CoA synthetase bubblegum family member 2.
Fig 4Heat map of differentially expressed genes between two groups.
Fig 5GO analysis of differentially expressed genes in breast muscle from two groups.
The number of genes for each GO annotation is shown in right axis, and the proportion of genes for each GO annotation is exhibited in left axis.
Enriched KEGG pathways and GO terms of DEGs in the breast muscle of broilers.
| Category | Term | Count | Enriched genes | |
|---|---|---|---|---|
| GO term | cholesterol metabolic process | 3 | 0.008 | |
| GO term | sterol metabolic process | 3 | 0.010 | |
| GO term | lipid biosynthetic process | 4 | 0.025 | |
| GO term | extracellular region part | 7 | 0.007 | |
| GO term | extracellular region | 8 | 0.036 | |
| KEGG pathway | Steroid biosynthesis | 3 | 0.004 | |
| KEGG pathway | Ether lipid metabolism | 3 | 0.024 | |
| KEGG pathway | Glycerolipid metabolism | 3 | 0.040 |
LSS, lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase); HSD17B7, hydroxysteroid (17-beta) dehydrogenase 7; DHCR24, 24-dehydrocholesterol reductase; ISPD, isoprenoid synthase domain containing; MVD, mevalonate (diphospho) decarboxylase; HTRA3, HtrA serine peptidase 3; TNXB, tenascin XB; MFAP5, microfibrillar associated protein 5; COL15A1, collagen, type XV, alpha 1; IL15, interleukin 15; ELN, elastin; MSTN, myostatin; FBN1, fibrillin 1; AGPAT2, 1-acylglycerol-3-phosphate O-acyltransferase 2; AGPAT6, 1-acylglycerol-3-phosphate O-acyltransferase 6; AGPAT3, 1-acylglycerol-3-phosphate O-acyltransferase 3.
Fig 6KEGG analysis of enriched pathways of differentially expressed genes between two groups.
Fig 7qRT-PCR analysis of differentially expressed genes from breast muscle of AA broilers.
MSTN, myostatin; MFAP5, microfibrillar associated protein 5; COL15A1, collagen, type XV, alpha 1; FBN1, fibrillin 1; DHCR24, 24-dehydrocholesterol reductase; HTRA3, HtrA serine peptidase 3; MVD, mevalonate (diphospho) decarboxylase; LSS, lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase); AGPAT2, 1-acylglycerol-3-phosphate O-acyltransferase 2; MYOT, myotilin. GAPDH was used as an internal control, data are presented as fold change (n = 3 per group).